Get the Stockscreener App
1.73
1.14%
-0.02
After Hours:
1.65
-0.08
-4.62%
Edesa Biotech Inc stock is traded at $1.73, with a volume of 23,838.
It is down -1.14% in the last 24 hours and down -21.36% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$1.75
Open:
$1.75
24h Volume:
23,838
Relative Volume:
0.81
Market Cap:
$6.00M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-0.6865
EPS:
-2.52
Net Cash Flow:
$-6.25M
1W Performance:
-10.65%
1M Performance:
-21.36%
6M Performance:
-59.39%
1Y Performance:
-64.48%
1-Day Range:
$1.55
$1.75
1-Week Range:
$1.55
$1.9921
52-Week Range:
$1.55
$5.99
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.73 | 6.00M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edesa Biotech Inc Stock (EDSA) Latest News
EDSA Stock Touches 52-Week Low at $1.69 Amid Market Challenges - Investing.com
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar - Simply Wall St
Edesa Biotech Inc. (EDSA) reports earnings - Quartz
Edesa Biotech Reports Fiscal Year 2024 Results - GlobeNewswire
Edesa Biotech Slashes Operating Costs 20%, Secures Government Backing for ARDS Drug Development - StockTitan
Edesa Biotech stock hits 52-week low at $2.02 amid challenges - Investing.com Nigeria
Edesa Biotech stock hits 52-week low at $2.02 amid challenges By Investing.com - Investing.com South Africa
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 192.2% - Defense World
EDSA stock touches 52-week low at $2.08 amid market challenges - Investing.com India
EDSA stock touches 52-week low at $2.08 amid market challenges By Investing.com - Investing.com South Africa
Edesa Biotech (NASDAQ:EDSA) Shares Up 4.7% – Here’s Why - Defense World
EDSA stock touches 52-week low at $2.27 amid market challenges - Investing.com Canada
Edesa Leaps as CEO Boosts Holdings - Baystreet.ca
Edesa Biotech CEO invests $5 million in company By Investing.com - Investing.com India
Edesa Biotech’s Founder Makes Strategic Investment in the Company - GlobeNewswire
Edesa Biotech to Present at Global Conferences - Nasdaq
Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewswire
Edesa Biotech Partners with Wainwright for Share Sales - TipRanks
Edesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38 - MSN
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? - MSN
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewswire Inc.
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
1 Dividend Stock to Invest in the Domestic Steel Market Now - The Globe and Mail
Celsius Holdings Inc (CELH-Q) QuotePress Release - The Globe and Mail
Mackenzie Investments Announces Results of Special Meetings on Mutual Fund and ETF Mergers - Yahoo Canada Finance
ECB interest rate cut likely as Eurozone economy weaker than expected - Yahoo Finance UK
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions - Yahoo Finance UK
Santander starts $1.7 billion share buyback programme - Yahoo Finance UK
FY2024 Earnings Estimate for Edesa Biotech, Inc. (NASDAQ:EDSA) Issued By HC Wainwright - Defense World
H.C. Wainwright bullish on Edesa Biotech stock amid BARDA study support - Investing.com
Edesa Biotech’s (EDSA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
500: Something went wrong - Investing.com UK
EDSA: EB05 Selected for BARDA-Funded Study in ARDS… - Zacks Small Cap Research
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Stock Price Down 2% - Defense World
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - XM
Ethiopian Airlines posts 14% jump in full-year revenue - Yahoo Finance UK
Alexis Shamess | Corporate/Commercial Lawyer in Toronto | People - Fasken
Myroslav Chwaluk | Mergers & Acquisitions Lawyer in Toronto | People - Fasken
A. Wojtek BaraniakPolish-speaking Corporate/Commercial lawyer in Toronto | People - Fasken
MoneySmart’s June Lucky Draw 2024 - Yahoo Finance
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Yahoo Finance UK
Homebuilder Vistry boosts output target as cost inflation softens - Yahoo Finance UK
German environmental authorities approve Tesla site expansion - Yahoo Finance UK
Cipher Pharmaceuticals - The Pharma Letter
Edesa Biotech (NASDAQ:EDSA) Receives Buy Rating from HC Wainwright - Defense World
Allied gaming executive Choi buys shares worth $778k By Investing.com - Investing.com
Bioventus exec sells over $14k in company stock By Investing.com - Investing.com
Edesa's Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS - Contract Pharma
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - StockTitan
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):